Guardant Complete
offers a comprehensive range of precision oncology tests.1-4
Product Selector
Discover all liquid and tissue testing options.
DetectionTreatment
SelectionMonitoring
Guardant Shield™
| SWIPE TO REVEAL FULL TABLE | |||
| FDA-Approved Guardant360® CDx1,5 | Guardant360®2,6,7 | Guardant360 TissueNext™3,8 | |
|---|---|---|---|
| INFORMATION PROVIDED | |||
| FDA-approved companion diagnostic with CGP of only 55 genes | Guides treatment selection with CGP test of 83 genes | Guides treatment selection with CGP of 84 genes | |
| FOR ANY SOLID TUMOR | |||
 | | | |
| LIQUID TEST | |||
| | N/A | |
| MEDICARE COVERAGE | |||
| | | |
| TURNAROUND TIME* | |||
| 7 days | 10 days | 2-3 weeks | |
Important Note: The Guardant Shield, Guardant Reveal, Guardant360 TissueNext, Guardant360 Response, and Guardant360 tests were developed, and performance characteristics determined, by the Guardant Health Clinical Laboratory in Redwood City, CA, USA, which is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as qualified to perform high-complexity clinical testing. Shield, Guardant Reveal, Guardant360 TissueNext, Guardant360 Response, and Guardant360 are Laboratory Developed Tests (LDT). These tests have not been cleared or approved by the US FDA. CGP, comprehensive genomic profiling. | |||
| Guardant Reveal™4,9-11 | Guardant360 Response™12 |
|---|---|
| INFORMATION PROVIDED | |
| Detects residual disease | Measures molecular response |
| FOR ANY SOLID TUMOR | |
| Stage II or III colorectal, breast, and lung cancer | |
| LIQUID TEST | |
| |
| MEDICARE COVERAGE | |
| Stage II or III colorectal cancer | N/A |
| TURNAROUND TIME* | |
| 2-3 weeks | 2 weeks |
Important Note: The Guardant Shield, Guardant Reveal, Guardant360 TissueNext, Guardant360 Response, and Guardant360 tests were developed, and performance characteristics determined, by the Guardant Health Clinical Laboratory in Redwood City, CA, USA, which is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as qualified to perform high-complexity clinical testing. Shield, Guardant Reveal, Guardant360 TissueNext, Guardant360 Response, and Guardant360 are Laboratory Developed Tests (LDT). These tests have not been cleared or approved by the US FDA. | |
| SWIPE TO REVEAL FULL TABLE | |||
| FDA-Approved Guardant360® CDx1,5 | Guardant360®2,6,7 | Guardant360 TissueNext™3,8 | |
|---|---|---|---|
| INFORMATION PROVIDED | |||
| FDA-approved companion diagnostic with CGP of only 55 genes | Guides treatment selection with CGP test of 83 genes | Guides treatment selection with CGP of 84 genes | |
| FOR ANY SOLID TUMOR | |||
| | | |
| LIQUID TEST | |||
| | N/A | |
| MEDICARE COVERAGE | |||
| | | |
| TURNAROUND TIME* | |||
| 7 days | 10 days | 2-3 weeks | |
Important Note: The Guardant Shield, Guardant Reveal, Guardant360 TissueNext, Guardant360 Response, and Guardant360 tests were developed, and performance characteristics determined, by the Guardant Health Clinical Laboratory in Redwood City, CA, USA, which is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as qualified to perform high-complexity clinical testing. Shield, Guardant Reveal, Guardant360 TissueNext, Guardant360 Response, and Guardant360 are Laboratory Developed Tests (LDT). These tests have not been cleared or approved by the US FDA. CGP, comprehensive genomic profiling. | |||
| Guardant Reveal™4,9-11 | Guardant360 Response™12 |
|---|---|
| INFORMATION PROVIDED | |
| Detects residual disease | Measures molecular response |
| FOR ANY SOLID TUMOR | |
| Stage II or III colorectal, breast, and lung cancer | |
| LIQUID TEST | |
| |
| MEDICARE COVERAGE | |
| Stage II or III colorectal cancer | N/A |
| TURNAROUND TIME* | |
| 2-3 weeks | 2 weeks |
Important Note: The Guardant Shield, Guardant Reveal, Guardant360 TissueNext, Guardant360 Response, and Guardant360 tests were developed, and performance characteristics determined, by the Guardant Health Clinical Laboratory in Redwood City, CA, USA, which is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as qualified to perform high-complexity clinical testing. Shield, Guardant Reveal, Guardant360 TissueNext, Guardant360 Response, and Guardant360 are Laboratory Developed Tests (LDT). These tests have not been cleared or approved by the US FDA. | |
Get critical insights about patients’ cancer
across the continuum.
SWIPE TO REVEAL FULL TABLE
First liquid-only biopsy for minimal residual disease (MRD) detection in early-stage settings.4
Explore product ›
First FDA-approved liquid-only comprehensive genomic profiling (CGP) for advanced-stage treatment selection.1,5
Explore product ›
Liquid-only CGP test for treatment selection in patients who have progressed on therapy.2
Explore product ›Download the guide to order both Treatment Selection and Monitoring tests from Guardant Complete.
*Turnaround times are most current best estimates based on actual sample processing times.
††Patient timeline is for illustrative purposes only.
‡‡Confirmation of medical necessity is required if Guardant360 TissueNext is ordered with another Guardant Health profiling test.
HRR, homologous recombinational repair; MSI, microsatellite instable; NTRK, neurotrophic tyrosine receptor kinase; PD-L1, programmed death-ligand 1; TMB, tumor mutation burden.